ArticlePharmacology research & perspectives2015

Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models.

Mukul R Jain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.